FDA clears Optovue’s epi-mapping software

Optovue’s epithelial thickness mapping software has become the first to be cleared by the FDA for quantitative measurements of the epithelial and stromal layers of the cornea, according to a company press release.

Aiding in the diagnosis, documentation and management of ocular health and diseases, epi-mapping provides epithelial thickness information in a fast, non-contact exam, the release said. It is available through the iVue and iFusion OCT systems.

“Our epi-mapping software has been the subject of more than 200 publications, underscoring its importance and value in the care of patients with corneal and ocular surface conditions,” Jay Wei, Optovue founder and CEO, said in the release. “With epi-mapping, physicians are able to quantify epithelial thickness in patients in a manner that is suitable for daily clinical practice.”

Optovue’s epithelial thickness mapping software has become the first to be cleared by the FDA for quantitative measurements of the epithelial and stromal layers of the cornea, according to a company press release.

Aiding in the diagnosis, documentation and management of ocular health and diseases, epi-mapping provides epithelial thickness information in a fast, non-contact exam, the release said. It is available through the iVue and iFusion OCT systems.

“Our epi-mapping software has been the subject of more than 200 publications, underscoring its importance and value in the care of patients with corneal and ocular surface conditions,” Jay Wei, Optovue founder and CEO, said in the release. “With epi-mapping, physicians are able to quantify epithelial thickness in patients in a manner that is suitable for daily clinical practice.”